These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 9198163)

  • 1. Recombinant factor IX.
    White GC; Beebe A; Nielsen B
    Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical studies of recombinant factor IX.
    Schaub R; Garzone P; Bouchard P; Rup B; Keith J; Brinkhous K; Larsen G
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):28-32. PubMed ID: 9565164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The manufacturing process for recombinant factor IX.
    Harrison S; Adamson S; Bonam D; Brodeur S; Charlebois T; Clancy B; Costigan R; Drapeau D; Hamilton M; Hanley K; Kelley B; Knight A; Leonard M; McCarthy M; Oakes P; Sterl K; Switzer M; Walsh R; Foster W
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):4-10. PubMed ID: 9565160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B.
    Lambert T; Recht M; Valentino LA; Powell JS; Udata C; Sullivan ST; Roth DA
    Haemophilia; 2007 May; 13(3):233-43. PubMed ID: 17498071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of recombinant factor IX.
    White G; Shapiro A; Ragni M; Garzone P; Goodfellow J; Tubridy K; Courter S
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):33-8. PubMed ID: 9565165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant factor IX for clinical and research use.
    Monahan PE; Di Paola J
    Semin Thromb Hemost; 2010 Jul; 36(5):498-509. PubMed ID: 20632248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical characterization of recombinant factor IX.
    Bond M; Jankowski M; Patel H; Karnik S; Strang A; Xu B; Rouse J; Koza S; Letwin B; Steckert J; Amphlett G; Scoble H
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):11-7. PubMed ID: 9565161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 9. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant factor IX for the treatment of hemophilia B. Introduction.
    Thompson A
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):1-3. PubMed ID: 9565159
    [No Abstract]   [Full Text] [Related]  

  • 11. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
    Aznar JA; Cabrera N; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañés M; Páez AM; Lissitchkov T
    Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Moret A; Caunedo P; Aznar JA; Woodward MK; Páez A
    Haemophilia; 2013 Sep; 19(5):674-8. PubMed ID: 23647607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.
    Windyga J; Abbuehl BE; Hafeman AE
    Expert Rev Hematol; 2014 Jun; 7(3):333-42. PubMed ID: 24832133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral safety of recombinant factor IX.
    Adamson S; Charlebois T; O'Connell B; Foster W
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):22-7. PubMed ID: 9565163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
    Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the treatment of haemophilia B: laboratory and clinical perspectives.
    Aledort LM
    Haemophilia; 2010 Jul; 16 Suppl 6():1-2. PubMed ID: 20561350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B.
    Liles D; Landen CN; Monroe DM; Lindley CM; Read MS; Roberts HR; Brinkhous KM
    Thromb Haemost; 1997 May; 77(5):944-8. PubMed ID: 9184407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
    Habart D
    Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7.
    Enjolras N; Perot E; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
    Haemophilia; 2015 Jul; 21(4):e317-21. PubMed ID: 25981983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.